CAS : 139755-83-2
Fórmula química: C22H19N3O4
Peso molecular: 389.4
Content: 99.5% Citrato de sildenafila, Viagra
Solubilidade: Slightly soluble in water, methanol; very slightly soluble in ethanol, chloroform
Aparência: Pó cristalino branco
Armazenar: sombreamento, preservação confinada.
Uso: Viagra (Citrato de sildenafila) é um medicamento usado para tratar a disfunção erétil (impotência) em homens e hipertensão arterial pulmonar (PAH).
Citrato de sildenafila, vendido como Viagra, Sildenafil é um medicamento oral para o tratamento da DE, usado no tratamento da disfunção erétil e ejaculação precoce, comprometimento da função erétil e ejaculação precoce apresentam melhorias muito significativas. Acabou 1500 documentos para comprovar a impotência causada por diferentes causas, a ejaculação precoce,sabia que a taxa de sucesso está acima 80%, e mostrar seu efeito curativo confiável, through the use of more than 20 million people worldwide, proved its long-term stability, the safety of 25 para 60 minutes of work function to coincide with a time needed for foreplay, knew the time adjustment in the highest drug concentration time, help both husband and wife a satisfactory sex life.
The primary indication of sildenafil is treatment of erectile dysfunction (inability to sustain a satisfactory erection to complete intercourse). Its use is now standard treatment for erectile dysfunction in all settings, including diabetes.It acts by inhibiting cGMP-specific phosphodiesterase type 5 (PDE5), an enzyme that promotes degradation of cGMP, which regulates blood flow in the penis.
As well as erectile dysfunction, sildenafil citrate is also effective in the rare disease pulmonary arterial hypertension. It relaxes the arterial wall, leading to decreased pulmonary arterial resistance and pressure. This, in turn, reduces the workload of the right ventricle of the heart and improves symptoms of right-sided heart failure. Because PDE5 is primarily distributed within the arterial wall smooth muscle of the lungs and penis, sildenafil acts selectively in both these areas without inducing vasodilation in other areas of the body. Pfizer submitted an additional registration for sildenafil to the United States Food and Drug Administration (FDA), and sildenafil was approved for this indication in June 2005. The preparation is named Revatio, to avoid confusion with Viagra, and the 20-mg tablets are white and round. Sildenafil joins bosentan and prostacyclin-based therapies for this condition.
